Delmer A, Zittoun R
Service d'hématologie, Hôtel-Dieu, Paris, France.
Bull Cancer. 1991;78(2):115-31.
Myelosuppression is the main limiting factor in cancer chemotherapy. The development of recombinant hematopoietic growth factors which stimulate myeloid progenitors and mainly neutrophil precursor cells leads to the evaluation of their potential activity in numerous fields of oncology. The available clinical trials have demonstrated the ability of G-CSF (granulocyte colony-stimulating factor) and GM-CSF (granulocyte-macrophage colony-stimulating factor) to accelerate neutrophil recovery following cytotoxic chemotherapy, and therefore to reduce the incidence of neutropenic febrile episodes and thereby improve the quality of life of patients receiving chemotherapy. The main goals of the future studies will be to determine to what extent the increase of dose intensity may lead to higher response rates and survival at least in patients with chemosensitive tumors.
骨髓抑制是癌症化疗的主要限制因素。刺激髓系祖细胞尤其是中性粒细胞前体细胞的重组造血生长因子的开发，促使人们评估其在肿瘤学众多领域的潜在活性。现有的临床试验已证明，粒细胞集落刺激因子（G-CSF）和粒细胞-巨噬细胞集落刺激因子（GM-CSF）能够加速细胞毒性化疗后中性粒细胞的恢复，从而降低中性粒细胞减少性发热事件的发生率，进而改善接受化疗患者的生活质量。未来研究的主要目标将是确定剂量强度增加在多大程度上至少能使化疗敏感肿瘤患者获得更高的缓解率和生存率。
